Bosun Asset Management LLC Acquires Shares of 9,194 Hims & Hers Health, Inc. $HIMS

Key Points

• Bosun Asset Management LLC acquired 9,194 shares of Hims & Hers Health, valued at approximately $272,000, indicating growing institutional interest in the company.
• Recent analyst ratings revealed varied opinions, with UBS setting a target price of $30.00, while Zacks downgraded the stock from "strong-buy" to "hold."
• Hims & Hers Health's stock increased by 8.5%, opening at $48.25; however, it reported EPS of $0.17, missing estimates by $0.01.

Bosun Asset Management LLC purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 9,194 shares of the company's stock, valued at approximately $272,000.

Several other institutional investors and hedge funds also recently made changes to their positions in HIMS. UMB Bank n.a. boosted its position in shares of Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after acquiring an additional 933 shares during the period. BI Asset Management Fondsmaeglerselskab A S bought a new position in Hims & Hers Health in the 1st quarter worth about $41,000. Larson Financial Group LLC increased its position in shares of Hims & Hers Health by 47.7% during the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock valued at $42,000 after purchasing an additional 458 shares during the last quarter. Tsfg LLC purchased a new stake in Hims & Hers Health in the 1st quarter worth approximately $46,000. Finally, Fifth Third Bancorp grew its holdings in Hims & Hers Health by 165.4% during the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock valued at $46,000 after buying an additional 961 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Stock Performance

Hims & Hers Health stock traded up $1.11 during trading hours on Monday, hitting $49.52. The stock had a trading volume of 29,761,120 shares, compared to its average volume of 33,179,309. Hims & Hers Health, Inc. has a fifty-two week low of $13.70 and a fifty-two week high of $72.98. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The company has a 50-day moving average of $50.03 and a two-hundred day moving average of $45.10. The company has a market cap of $11.19 billion, a PE ratio of 62.09, a price-to-earnings-growth ratio of 3.27 and a beta of 2.14.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same period in the prior year, the business earned $0.06 earnings per share. The company's revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on HIMS. Truist Financial cut their price target on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research note on Monday, August 18th. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Morgan Stanley restated an "equal weight" rating and set a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Finally, Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Two research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of "Reduce" and a consensus target price of $38.92.

Insiders Place Their Bets

In related news, insider Soleil Boughton sold 2,571 shares of the business's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $44.53, for a total value of $114,486.63. Following the completion of the sale, the insider directly owned 150,450 shares in the company, valued at approximately $6,699,538.50. The trade was a 1.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Patrick Harrison Carroll sold 60,000 shares of the company's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the transaction, the insider owned 169,940 shares of the company's stock, valued at $9,105,385.20. This trade represents a 26.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,390,328 shares of company stock valued at $71,468,298 in the last quarter. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.